Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the associazione italiana ematologia oncologia pediatrica '82 studies

Abstract

This risk-directed therapy cured at least 50% of patients with ALL with relatively nonintensive therapy. The 80% overall survival rate for LR and AR patients at 7 years suggested that the total cure rate may be higher than 50% because of the significant salvage rate for patients who received antimetabolite-based therapy initially.